Benedicto Crespo-Facorro1,2, Miguel Ruiz-Veguilla1,2, Javier Vázquez-Bourgon2,3,4, Ana C Sánchez-Hidalgo2,5, Nathalia Garrido-Torres1, Jose M Cisneros6,7, Carlos Prieto8, Jesus Sainz9. 1. Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain. 2. Spanish Network for Research in Mental Health (CIBERSAM), Sevilla, Spain. 3. Department of Psychiatry, University Hospital Marques de Valdecilla - Instituto de Investigacion Marques de Valdecilla (IDIVAL), Santander, Spain. 4. Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. 5. Seville Biomedical Research Centre (IBiS), Sevilla, Spain. 6. Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University of Seville, Salamanca, Spain. 7. Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain. 8. Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain. 9. Spanish National Research Council (CSIC), Institute of Biomedicine and Biotechnology of Cantabria, Santander, Spain.
Abstract
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID-19-related immunological parameters. Methods: Differential gene expression profiles of non-COVID-19 vs. COVID-19 RNA-Seq samples (CRA002390 project in GSA database) and drug-naïve patients with non-affective psychosis at baseline and after three months of aripiprazole treatment were identified. An integrative transcriptomic analyses of aripiprazole effects on differentially expressed genes in COVID-19 patients was performed. Findings: 82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. The number of common genes with expression altered in both analyses is significantly higher than expected (Fisher's Exact Test, two tail; p value = 3.2e-11). 11 KEGG pathways were significantly enriched with genes with altered expression both in COVID-19 patients and aripiprazole medicated non-affective psychosis patients (p adj<0.05). The most significant pathways were associated to immune responses and mechanisms of hyperinflammation-driven pathology (i.e.,"inflammatory bowel disease (IBD)" (the most significant pathway with a p adj of 0.00021), "Th1 and Th2 cell differentiation" and "B cell receptor signaling pathway") that have been also associated with COVID19 clinical outcome. Interpretation: This exploratory investigation may provide further support to the notion that a protective effect is exerted by aripiprazole (phenylpiperazine) by modulating the expression of genes that have shown to be altered in COVID-19 patients. Along with many ongoing studies and clinical trials, repurposing available medications could be of use in countering SARS-CoV-2 infection, but require further studies and trials.
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID-19-related immunological parameters. Methods: Differential gene expression profiles of non-COVID-19 vs. COVID-19 RNA-Seq samples (CRA002390 project in GSA database) and drug-naïve patients with non-affective psychosis at baseline and after three months of aripiprazole treatment were identified. An integrative transcriptomic analyses of aripiprazole effects on differentially expressed genes in COVID-19 patients was performed. Findings: 82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. The number of common genes with expression altered in both analyses is significantly higher than expected (Fisher's Exact Test, two tail; p value = 3.2e-11). 11 KEGG pathways were significantly enriched with genes with altered expression both in COVID-19 patients and aripiprazole medicated non-affective psychosis patients (p adj<0.05). The most significant pathways were associated to immune responses and mechanisms of hyperinflammation-driven pathology (i.e.,"inflammatory bowel disease (IBD)" (the most significant pathway with a p adj of 0.00021), "Th1 and Th2 cell differentiation" and "B cell receptor signaling pathway") that have been also associated with COVID19 clinical outcome. Interpretation: This exploratory investigation may provide further support to the notion that a protective effect is exerted by aripiprazole (phenylpiperazine) by modulating the expression of genes that have shown to be altered in COVID-19 patients. Along with many ongoing studies and clinical trials, repurposing available medications could be of use in countering SARS-CoV-2 infection, but require further studies and trials.
Authors: Jennifer Harrow; Adam Frankish; Jose M Gonzalez; Electra Tapanari; Mark Diekhans; Felix Kokocinski; Bronwen L Aken; Daniel Barrell; Amonida Zadissa; Stephen Searle; If Barnes; Alexandra Bignell; Veronika Boychenko; Toby Hunt; Mike Kay; Gaurab Mukherjee; Jeena Rajan; Gloria Despacio-Reyes; Gary Saunders; Charles Steward; Rachel Harte; Michael Lin; Cédric Howald; Andrea Tanzer; Thomas Derrien; Jacqueline Chrast; Nathalie Walters; Suganthi Balasubramanian; Baikang Pei; Michael Tress; Jose Manuel Rodriguez; Iakes Ezkurdia; Jeltje van Baren; Michael Brent; David Haussler; Manolis Kellis; Alfonso Valencia; Alexandre Reymond; Mark Gerstein; Roderic Guigó; Tim J Hubbard Journal: Genome Res Date: 2012-09 Impact factor: 9.043
Authors: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Lars Pache; Sebastian Burgstaller-Muehlbacher; Paul D De Jesus; Peter Teriete; Mitchell V Hull; Max W Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina M Herbert; Kuoyuan Cheng; Tu-Trinh H Nguyen; Andrey Rubanov; Yuan Pu; Courtney Nguyen; Angela Choi; Raveen Rathnasinghe; Michael Schotsaert; Lisa Miorin; Marion Dejosez; Thomas P Zwaka; Ko-Yung Sit; Luis Martinez-Sobrido; Wen-Chun Liu; Kris M White; Mackenzie E Chapman; Emma K Lendy; Richard J Glynne; Randy Albrecht; Eytan Ruppin; Andrew D Mesecar; Jeffrey R Johnson; Christopher Benner; Ren Sun; Peter G Schultz; Andrew I Su; Adolfo García-Sastre; Arnab K Chatterjee; Kwok-Yung Yuen; Sumit K Chanda Journal: Nature Date: 2020-07-24 Impact factor: 69.504
Authors: Cintia R Prokopez; Romina Farinola; Miguel Vallejos; Lorena S Lopredo; Luciano E Sfriso; Luciana C Chiapella; Claudio Arce; Ricardo M Corral; Manuel J Cuesta; Martín Alomo Journal: Schizophr Res Date: 2022-01-24 Impact factor: 4.939
Authors: A Costanza; A Amerio; A Aguglia; G Serafini; M Amore; R Hasler; J Ambrosetti; G Bondolfi; G Sampogna; I Berardelli; A Fiorillo; M Pompili; K D Nguyen Journal: Neurosci Biobehav Rev Date: 2022-03-12 Impact factor: 9.052
Authors: Benedetta Vai; Mario Gennaro Mazza; Casanova Dias Marisa; Julian Beezhold; Hilkka Kärkkäinen; John Saunders; Jerzy Samochowiec; Francesco Benedetti; Marion Leboyer; Paolo Fusar-Poli; Livia De Picker Journal: Eur Psychiatry Date: 2022-08-16 Impact factor: 7.156